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PCoronary Microvascular Reactivity
to Adenosine Predicts Adverse Outcome
in Women Evaluated for Suspected Ischemia
Results From the National Heart, Lung and Blood
Institute WISE (Women’s Ischemia Syndrome Evaluation) Study
Carl J. Pepine, MD,* R. David Anderson, MD,* Barry L. Sharaf, MD,† Steven E. Reis, MD,‡
Karen M. Smith, MD,* Eileen M. Handberg, PHD,* B. Delia Johnson, PHD,‡
George Sopko, MD, MPH,§ C. Noel Bairey Merz, MD
Gainesville, Florida; Providence, Rhode Island; Pittsburgh, Pennsylvania; and Los Angeles, California
Objectives We investigated whether coronary microvascular dysfunction predicts major adverse outcomes during follow-up
among women with signs and symptoms of ischemia.
Background Altered coronary reactivity occurs frequently in women evaluated for suspected ischemia, and the endothelium-
dependent component is linked with adverse outcomes. Possible links between endothelium-independent micro-
vascular coronary reactivity and adverse outcomes remain uncertain.
Methods As part of the National Heart, Lung and Blood Institute-sponsored WISE (Women’s Ischemia Syndrome Evalua-
tion), we investigated relationships between major adverse outcomes and baseline coronary flow reserve (CFR)
after intracoronary adenosine in 189 women referred to evaluate suspected ischemia.
Results At a mean of 5.4 years, we observed significant associations between CFR and major adverse outcomes (death, non-
fatal myocardial infarction, nonfatal stroke, or hospital stay for heart failure). An exploratory receiver-operator charac-
teristic analysis identified CFR 2.32 as the best discriminating threshold for adverse outcomes (event rate 26.7%;
and 2.32 event rate 12.2%; p  0.01). Lower CFR was associated with increased risk for major adverse outcomes
(hazard ratio: 1.16, 95% confidence interval: 1.04 to 1.30; p  0.009). This held true among the 152 women without
obstructive coronary artery disease (CAD) (hazard ratio: 1.20, 95% confidence interval: 1.05 to 1.38; p  0.008). The
CFR significantly improved prediction of adverse outcomes over angiographic CAD severity and other risk conditions.
Conclusions Among women with suspected ischemia and atherosclerosis risk factors, coronary microvascular reactivity to
adenosine significantly improves prediction of major adverse outcomes over angiographic CAD severity and CAD risk
factors. These findings suggest that coronary microvessels represent novel targets for diagnostic and therapeutic
strategies to predict and limit adverse outcomes in women. (Women’s Ischemia Syndrome Evaluation [WISE];
NCT00000554) (J Am Coll Cardiol 2010;55:2825–32) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.054c
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and disability (1). Although
knowledge of mechanisms ex-
plaining these findings is lim-
ited, impaired coronary reactiv-
ity (endothelium- and non–
endothelium-dependent) has been
proposed to contribute (2–10).
The endothelium-dependent com-
ponent has been linked to risk fac-
tors and proinflammatory pro-
cesses promoting atherosclerosis
(8,9) as well as adverse clinical
outcomes (5,7,10). Although the
non–endothelium-dependent com-
ponent has received less attention,
the concept that patients with risk
factors might have evidence for
reduced coronary flow reserve
CFR) is not new (11–17). There is increasing interest in this
icrovascular response, as recently reviewed elsewhere (18),
nd in particular the response among women (8). For example,
ypercholesterolemia abolishes the voltage-dependent K
hannel contribution to adenosine-mediated smooth muscle
elaxation, in both endothelium-intact and -denuded coronary
rterioles, in a sex-specific manner (19,20). Vascular smooth
uscle cells undergo alterations in phenotype in response to
hysiological and pathophysiological stimuli like hypertension
nd diabetes, which are highly prevalent in post-menopausal
omen, as well as estrogen receptor alpha expression (21,22).
Myocardial perfusion alterations during adenosine-induced
asodilation are not infrequent in the absence of significant
picardial CAD (23,24). Although there has been long
nterest in microvascular ischemia, most work has focused
n the endothelium-dependent component (25–28), but
denosine-related vascular smooth muscle alterations do not
ecessarily correlate with dysfunctional endothelium
8,20,29). Thus, additional information on adenosine-
elated coronary microvascular reactivity would facilitate an
mproved understanding of processes underlying these vas-
ular alterations in women. If these alterations contribute to
dverse outcomes, they potentially offer an important target
or risk stratification and evaluation of preventive treatments
mong these women, particularly now that coronary micro-
ascular reactivity can be readily assessed noninvasively
30–32).
Accordingly, we investigated the relationship between
denosine-coronary reactivity at baseline and adverse out-
omes during follow-up in women referred for coronary
ngiography.
ethods
he WISE (Women’s Ischemia Syndrome Evaluation)
tudy is a National Heart, Lung and Blood Institute-
Abbreviations
and Acronyms
CAD  coronary artery
disease
CFR  coronary flow
reserve
CHF  congestive heart
failure
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
LV  left ventricular
MBF  myocardial blood
flow
MI  myocardial infarction
ROC  receiver-operator
characteristicponsored study aimed at improving diagnostic evaluation and understanding of pathological mechanisms of ischemic
eart disease in women, and protocol details—including
election criteria—have been previously published (33). Site
nstitutional review boards approved the study, and each
articipant provided written informed consent. Women
ges 18 to 84 years undergoing clinically-indicated angio-
rams were enrolled, underwent a variety of testing, and
ere followed for clinical outcomes. A subgroup of 189
omen from the Universities of Florida and Pittsburgh sites
lso had evaluation of coronary reactivity to adenosine.
heir selection criteria also included informed consent for
his additional testing, absence of stenosis warranting cor-
nary revascularization, and an appropriate coronary seg-
ent for Doppler flow testing.
Baseline evaluation included physical examination and
ollection of clinical and laboratory data (Table 1). Inflam-
atory markers were measured in a subgroup of 134 women
rom blood frozen on site at 70°C and analyzed at a core
aboratory with validated techniques. Qualitative and quan-
itative coronary angiographic analyses were done by a core
aboratory masked to patient data (34). Any50% diameter
tenosis was defined as obstructive CAD, 20% to 49% as
ild CAD, and 20% as no CAD. A CAD severity score
as defined as an aggregate of percent stenosis, extent and
ocation of stenosis, and degree of collateral vessels (34).
Coronary reactivity testing was performed in a stenosis-
ree area of the left anterior descending coronary artery (n
38) when possible, with the left circumflex artery as a
econdary choice. A Doppler-tipped guidewire (0.014-inch
loWire, JOMED/Cardiometrics, Mountain View, Cali-
ornia) was advanced through the diagnostic catheter. Once
stable velocity signal was obtained, baseline recordings
ere made. Intracoronary bolus injections of 18 g of
denosine (Adenocard, Fujisawa USA, Deerfield, Illinois), a
redominantly non–endothelium-dependent microvascular
ilator, were administered into the left main coronary artery
35). At least 3 injections were done to ensure that a stable
verage peak coronary flow velocity was obtained after
denosine, with return to baseline flow velocity documented
efore each bolus. Pulsed-wave Doppler flow spectra were
sed to calculate time-averaged peak velocity. Recordings
ere analyzed at a core laboratory (University of Florida)
asked to all other data, and CFR was defined as the ratio
f average peak velocity after adenosine to average baseline
elocity just before adenosine. As this measure correlated
losely (r  0.87, p  0.001) with volumetric flow (35), it
as used to represent CFR.
To access the possible influence of left ventricular (LV)
ypertrophy on CFR, 39 of these women without coronary
tenosis had quantitative analysis of echocardiograms per-
ormed with a standardized protocol within several days of
FR measurements according to American Society of
chocardiography recommendations. These analyses in-
luded measurement of LV mass (2-dimensional echocar-
iography) determined by an anatomically validated short-
xis area length method (36), mass index, and an index of
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June 22, 2010:2825–32 Coronary Microvascular Reactivity in WomenV concentric remodeling (end-diastolic ratio of short-axis
yocardial to cavity area). All echocardiography measure-
ents were done at a core laboratory masked to patient data.
dverse outcomes during follow-up. During protocol-
irected yearly follow-up, records of women reporting an
vent were reviewed by an events committee and tabulated
s death; nonfatal myocardial infarction (MI); nonfatal
troke; and hospital stay for congestive heart failure (CHF),
ngina, and other vascular events. Women sustaining mul-
iple events were counted only once and by the initial event.
hose with death, nonfatal MI, nonfatal stroke, or CHF
ospital stay were categorized as having major adverse
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
All Women
(n  189)
Age, yrs 55 10
Yrs since last menses 16 11
White/Caucasian 83
Body mass index (kg/m2) 31.2 7.4
SBP (mm Hg) 136 20
DBP (mm Hg) 77 10
Family history of premature CAD 69
History of
Diabetes 21
Hypertension 57
Dyslipidemia 50
Current smoking 19
Past smoking 37
Menopause 76
Blood assays
Total cholesterol (mg/dl) 185 44
HDL cholesterol (mg/dl) 52 12
LDL cholesterol (mg/dl) 107 37
Triglycerides (mg/dl) 141 141
Plasma glucose (mg/dl) 105 48
Hemoglobin (g/dl) 13.0 1.4
Serum creatinine (mg/dl) 0.8 0.5
Serum amyloid A (mg/dl) 1.0 2.3
C-reactive protein (mg/l) 7.8 11.6
Interleukin-6 (pg/ml) 3.7 2.8
Medication use, currently
Aspirin 50
Statin 16
ACE inhibitor 24
Beta-blocker 29
Hormone use, ever
Hormone replacement 56
Oral contraceptives 60
Ejection fraction 64.7 9.6
CAD
None (20% stenosis) 51
Mild (20%–49% stenosis) 30
Obstructive (50% stenosis) 19
CAD severity score, median (IQR) 5.0 (5.0–9.2)
Data expressed as mean  SD or percentage unless otherwise noted
ACE  angiotensin-converting enzyme; CAD  coronary artery
HDL  high-density lipoprotein; IQR  interquartile range; LDL  lowutcomes. Categorization of deaths as cardiovascular (CV) Las made only when documentation definitely confirmed
hat death was due to CV causes.
tatistical analyses. Values are expressed as mean SD or
ercentages as indicated, and the t test or chi-square
nalysis, where appropriate, was used to evaluate differences
mong groups. The CAD angiographic severity score was
on-normally distributed and was expressed as medians and
nterquartile ranges with differences among groups evalu-
ted by the Kruskal-Wallis test. To determine the CFR
alue best predictive of major adverse outcomes (death, MI,
troke, or hospital stay for CHF), we generated a receiver-
perator characteristic (ROC) curve from the PROC
CFR <2.32
(n  74)
CFR >2.32
(n  115) p Value
58 10 54 10 0.02
19 12 14 10 0.004
88 80 0.16
31.2 6.3 31.2 8.0 0.67
139 23 134 18 0.08
77 9 76 11 0.93
71 67 0.61
26 18 0.24
58 56 0.79
54 48 0.51
16 20 0.50
39 35 0.57
81 72 0.18
188 45 183 42 0.39
53 12 52 13 0.84
111 40 104 36 0.16
148 118 136 155 0.72
108 52 102 44 0.34
13.0 1.6 13.0 1.3 0.35
0.8 0.3 0.8 0.6 0.35
1.1 2.6 1.0 2.1 0.06
8.8 13.7 7.2 10.2 0.22
3.9 3.0 3.6 2.6 0.72
57 46 0.14
19 15 0.47
27 23 0.51
36 24 0.06
53 58 0.53
60 59 0.88
64.5 10.9 64.9 8.8 0.71
46 54
28 32
26 15 0.11
7.5 (5.0–11.2) 5.0 (5.0–8.0) 0.036
; CFR  coronary flow reserve; DBP  diastolic blood pressure;
lipoprotein; SBP  systolic blood pressure..OGISTIC function in SAS (SAS Institute, Cary, North
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Coronary Microvascular Reactivity in Women June 22, 2010:2825–32arolina), which calculates area under the curve, indicated
y the c-statistic, with the trapezoidal rule. The CFR value
orresponding to the point on the curve closest to 100%
ensitivity and specificity was matched, first by visual means
nd then by verification runs of incremental cut-points near
his value. The discriminating threshold by ROC analysis
as then used to categorize women into low versus high
FR groups. Kaplan-Meier analysis was used to compare
ime to adverse event by CFR group in all women and in
omen without obstructive CAD. Multivariate Cox pro-
ortional hazards regression was used to examine the role of
aseline characteristics, including the natural logs of both
he CAD severity score and CFR (logCFR  10) on
dverse outcomes. Baseline characteristics (Table 1) were
hosen for entry into multivariable Cox models on the basis
f their discrimination between low and high CFR as well
s on univariate associations with adverse outcomes of p 
.20. A combination of forward and backward selection
rocedures was used to aid in determining the best model of
ndependent predictors. This was followed by forcing po-
ential confounders, including drugs used at baseline and
uring follow-up, into the models and determining their
ffect on the relationship of interest. The likelihood ratio
est was used to compare the incremental goodness of fit of
ested models. All tests were 2-sided, and p  0.05 was
onsidered statistically significant. All analyses were per-
ormed with SAS software version 9.1 (SAS Institute).
esults
aseline characteristics. Pertinent characteristics of the
omen are summarized in Table 1. Their mean age was 55
10 years; most were white; about three-quarters were
ost-menopausal; and more than one-half were obese (body
ass index 30 kg/m2), had a history of hypertension or
yslipidemia, had a family history of premature heart
isease, or had ever used hormone replacement or oral
ontraceptive pills. A history of diabetes was present in
pproximately one-fifth. Approximately one-half were cur-
ently taking aspirin; approximately one-quarter were cur-
ently taking angiotensin-converting enzyme inhibitors; less
han one-third were currently taking beta-blockers; and
pproximately one-fifth were currently taking statins.
ngiographic CAD, echocardiography LV mass, and
FR. Most (152 or 81%) of the women had either no or
50% obstructive CAD (Table 1), and lower CFR was
eakly associated with higher CAD severity score (rs 
0.15, p  0.04). In comparison of groups with obstruc-
ive, mild, or no angiographic CAD, the CFRs were 2.3 
.7, 2.5  0.7, and 2.6  0.7, respectively (p  0.09 for
rend). Regression analyses and comparisons of subgroups
ith normal versus elevated LV mass, mass index, and
nd-diastolic ratio of short-axis myocardial to cavity area
howed no significant relationships between LV mass vari-
bles and CFR (data not shown). idverse outcomes by risk factors and CFR. During
ollow-up (mean 5.4 years), 79 women (42%) had an adverse
utcome, and in total there were 138 events, including 11
eaths (Table 2). Thirty-four of these 79 women had major
dverse outcomes (death, MI, stroke, or hospital stay for
HF). Note that 25 of the women without obstructive
AD had major adverse outcomes.
All analyses summarized in the following text were done
ith only major adverse outcomes. Substituting definite CV
eaths for all-cause deaths produced very similar results.
Among all women in this cohort, those with major
dverse events during follow-up had at baseline higher
ystolic blood pressure (p  0.01), C-reactive protein (p 
.038), and interleukin-6 (p  0.02) levels and CAD
everity scores (p  0.0009) and were more frequently
ost-menopausal (p  0.02) compared with those without
vents. Similar trends were found among the subgroup
ithout obstructive CAD, but only post-menopausal status
p  0.025) and higher CAD severity score (p  0.0005)
eached statistical significance, due to smaller sample size
ith fewer events.
By ROC analysis, a CFR 2.32 provided the best
rediction, with a sensitivity of 62% and specificity of 65%,
or major adverse outcomes (CFR 2.32 outcomes rate
7.0% and 2.32 outcomes rate 12.2%, chi-square  6.73,
 0.010). The area under the curve was 0.63 (95%
onfidence interval: 0.53 to 0.73). Similar results were
btained when restricting the analysis to women without
bstructive CAD: women with low CFRs experienced
ignificantly more major adverse outcomes (CFR 2.32
utcome rate 26.6% vs. 9.3%, chi-square  5.84; p 
.016). Women with low CFR were older (p  0.02) and
ad a higher CAD severity (p  0.036) versus those with
igh CFR. There was a significant decline over time in
reedom from major events for women with lower (2.32)
FR compared with those with higher CFR (p  0.003)
Fig. 1), which remained consistent after adjusting for
ndex (First) and Total Adverse Eventsuring ollow-UpTable 2 Index (First) and Total Adverse EventsDuring Follow-Up
Events
Number of Index
(First) Events
Total Number
of Events
Major events
Death 8 11
Hospital stay for nonfatal event
MI 3 7
CHF 6 18
Stroke 8 10
Other events
PCI 12 23
CABG 1 4
Angina 36 52
Other vascular event 5 13
Total (%) 79 (42%) 138*
Total (n  138) events in 79 women.
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure; MI  myocardial
nfarction; PCI  percutaneous coronary intervention.
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June 22, 2010:2825–32 Coronary Microvascular Reactivity in Womenisk factors (systolic blood pressure, CAD severity, age,
iabetes, and smoking). The Cox proportional hazard-
djusted time-to-event curves are similar to the unad-
usted Kaplan-Meier curves shown in Figure 1, and the p
alues remain significant.
When used as a continuous variable, low CFR also
ignificantly predicted increased risk for major adverse
utcomes (Table 3). For each 0.1-U decrease in logCFR,
he relative risk for major adverse outcomes increased by
0% among women without obstructive CAD.
Multivariate Cox regression modeling (Table 4) identi-
ed only logCFR (p 0.043), log CAD severity score (p
.058), and systolic blood pressure (p  0.012) as indepen-
ent predictors of major adverse outcome. When multiple
AD risk conditions (e.g., age, history of diabetes, and
moking) were forced into the model, potentially overfitting
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Figure 1 CFR and Event-Free Survival
Coronary flow reserve (CFR) and event-free survival among all women (A) and
those without coronary artery disease (CAD) (B). Data represent unadjusted
Kaplan-Meier curves for absence of death, nonfatal myocardial infarction, non-
fatal stroke, or hospital stay for congestive heart failure during follow-up.he model, CFR remained a significant predictor (p  m.038), whereas the effect of log CAD severity was attenu-
ted. No other risk factors contributed (data not shown).
hen any statin, angiotensin-converting enzyme inhibitor,
nd beta-blocker use were forced into the models, use of
hese drugs was neither a significant predictor of adverse
utcome nor an influence on relationship between CFR and
dverse outcome. In the combined model, the likelihood
atio test determined that adding CFR significantly im-
roved prediction of major adverse outcomes over the other
ariables (chi-square  4.37; p  0.036).
iscussion
any women presenting with ischemic-type symptoms and
igns do not have obstructive CAD but have impaired
oronary reactivity to adenosine, which has the potential to
imit myocardial flow, yet an association with adverse
utcome is unclear. Most reports did not examine
ndothelium-independent microvascular responses, few pa-
ients had major serious events (most were revasculariza-
ion), relatively few women were included, and/or sex-
pecific data were not reported.
Nitenberg et al. (3) published CV outcome in hyperten-
ive and diabetes patients without CAD using cold-pressor
esting with epicardial coronary diameter measurements,
hich is related both to endothelial- and non–endothelial-
ependent mechanisms, but no sex stratification or flow
esponses were reported. Halcox et al. (2) found a significant
ssociation between acetylcholine responses and outcomes.
lthough trends were noted for nitroprusside and adeno-
ine, they concluded in this underpowered study that
ndothelium-independent responses were not predictive of
utcome (2). Al Suwaidi et al. (6) reported the prognostic
alue of the response to adenosine and nitroprusside but
imply stated that CFR response to adenosine was signifi-
antly lower in those with endothelial dysfunction, implying
hat endothelial-dependent and -independent mechanisms
how similar responses.
Other studies indicate that positron emission tomography
easures of absolute myocardial blood flow (MBF) and
FR or myocardial perfusion reserve (1,2,5,7,10,14) might
e abnormal in individuals with risk factors without appar-
nt CAD. Overall, these reports document reduced coro-
ary reactivity in individuals with a greater coronary risk
actor burden. Except for a report (5) suggesting that
mpaired MBF responses to cold-pressor testing were asso-
iated with increased risk of events, the prognostic value of
raditional clinical risk assessment versus myocardial perfu-
ion reserve by positron emission tomography cannot be
ompared because of lack of follow-up data. Additionally,
ther studies (37) have demonstrated that maximum MBF
nd CFR might be impaired in myocardial territories
upplied by arteries that do not appear obstructed in patients
ith obstructive CAD elsewhere. Finally, reduced MBF
eserve in patients with hypertrophic (9) or dilated cardio-
yopathy (29) has predictive value for prognosis. Thus, the
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Coronary Microvascular Reactivity in Women June 22, 2010:2825–32verall topic of coronary microvascular dysfunction and its
linical implications has increasing interest (11–13,15–
8,38–43).
A better understanding of adverse outcomes associated
ith dysfunctional microvessels could help to clarify the
athophysiology of ischemic heart disease in women and
erhaps identify new targets for both diagnostic testing and
herapeutic intervention.
Our findings indicate that endothelium-independent
FR is a predictor of major adverse outcomes in the women
tudied. The link between CFR and major adverse out-
omes remained, regardless of presence or absence of
bstructive CAD or multiple risk conditions. The low but
ignificant association of this component of coronary reac-
ivity with CAD severity is intriguing, because atheroscle-
otic plaque is usually localized to conduit arteries and those
elected for flow measurement did not have flow-limiting
tenoses. Furthermore, among the 152 women without any
bstructive stenoses, the link with adverse outcomes re-
ained significant. Although adenosine receptors are
resent in both endothelial and smooth muscle cells, it is
nlikely that dilation of conduit arteries, through either an
ndothelial or smooth muscle mechanism, could explain our
ndings. Thus, the location of the defect exposed by
denosine in these women is most likely at the microvascu-
ar level. This might represent an early manifestation of
ascular defects underlying ischemic heart disease in these
omen, with the potential to contribute to subsequent
ajor adverse outcomes even in the absence of conduit
Decreasing LogCFR and Risk for Adverse OutcoTable 3 Decreasing LogCFR and Risk for Ad
Outcome
All women
Major adverse outcome*
CV death, nonfatal MI, nonfatal stroke, or hospital stay fo
CV death, nonfatal MI, or hospital stay for CHF
Women without obstructive CAD
Major adverse outcome*
CV death, nonfatal MI, nonfatal stroke, or hospital stay fo
CV death, nonfatal MI, or hospital stay for CHF
Unadjusted Cox regression analyses. *Death, nonfatal MI, nonfatal str
CI  confidence interval; CV  cardiovascular; other abbreviations
ultivariate Modeling of Major EventsTable 4 ultivariate odeling of Major Events
Model 1
Predictor HR (95% CI) p Value
LogCFR 1.15 (1.02–1.30) 0.018 1
SBP 1.02 (1.005–1.04) 0.011 1
Log CAD severity — — 1
Age — —
History of diabetes — —
Ever smoked — —
ox regression analysis. When interpreting these tables, the hazard ratios (HRs) reflect the percen
ther variables in Table 1 did not substantially change the relationship between CFR and major adverse
SBP  systolic blood pressure; other abbreviations as in Tables 1 and 2.essel obstruction. Indeed, women in the WISE cohort,
ncluding those without obstructive CAD, had a surpris-
ngly high risk for major adverse events during follow-up
44,45). A possible conclusion from this analysis is that
onobstructive CAD (49% diameter stenosis) in women
s perhaps of greater importance than can be surmised
erely from speculation about conduit artery hemodynamic
mpairment (or lack thereof). Such findings seem to be
ssociated with evidence of microvascular disease and a
oorer outcome. Presence of such findings in women might
arrant CFR measurements to refine estimates of progno-
is. Alternatively, a lower percentage narrowing threshold
or CAD score) might be identified in such women that
ight be useful for prognostic purposes (even if not useful
or intervention purposes).
It would be highly desirable to have a simple reliable
hysiologic measure to identify women at highest risk for
dverse outcomes, and this measure could be altered coronary
icrovascular reactivity. If proven so in other studies, this could
ead to more targeted treatment and the reactivity measure-
ent could be noninvasively performed and followed to assess
esponse to treatment and prevention strategies.
Other evidence implicates the coronary microcirculation to
xplain some findings in ischemic heart disease that are
bserved in women (46). In the absence of conduit vessel
bstruction, this includes myocardial metabolic, electrocardio-
raphic, and scintigraphic evidence for ischemia (47); histo-
ogic evidence for small vessel disease (48); the predictive value
f brain natriuretic peptide and C-reactive protein for adverse
Outcomes
Hazard Ratio 95% CI p Value
1.16 1.04–1.30 0.009
1.15 1.02–1.30 0.019
1.18 1.03–1.36 0.018
1.20 1.05–1.38 0.008
1.19 1.03–1.37 0.020
1.23 1.03–1.47 0.021
hospital stay for CHF.
bles 1 and 2.
Model 2 Model 3
95% CI) p Value HR (95% CI) p Value
.004–1.27) 0.043 1.14 (1.01–1.29) 0.038
.004–1.04) 0.012 1.02 (1.001–1.04) 0.035
.98–2.88) 0.058 1.61 (0.92–2.81) 0.10
— — 1.00 (0.96–1.04) 0.90
— — 1.44 (0.65–3.20) 0.37
— — 1.22 (0.60–2.46) 0.58
ange in events for every 0.1-U increment in the logCFR. Adjusting for 1 covariate at a time amongmesverse
r CHF
r CHFHR (
.13 (1
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omen dying with acute coronary syndromes (50). Even more
mportant is the question: could microvascular dysfunction
eteriorate into or perhaps promote macrovascular disease?
tudy limitations. Although this study represents the larg-
st group of women with microvascular reactivity and
ollow-up data reported, we evaluated a relatively select
ohort with ischemic-type symptoms and multiple risk
onditions prompting referral for angiography. This indica-
ion bias limits generalization of results. Unknown factors,
ncluding individual variability in dose responses or in
ascular smooth muscle effects of similar CAD risk condi-
ions, could potentially affect CFR. Although adenosine-
nduced CFR increases are mediated largely via smooth
uscle relaxation, endothelium-dependent mechanisms
ould contribute (51). It is likely that the 18-g intracoro-
ary adenosine dose might not have achieved near maximal
yperemia in every patient. Similar adenosine doses provide
ear maximal increase in flow in 90% to 92% of cases (52),
nd larger doses used for fractional flow reserve measure-
ent to assess coronary stenosis severity might provide
ifferent results. Left ventricular hypertrophy might influ-
nce coronary microvascular reactivity; however, quantita-
ive echocardiographic analysis from a subgroup of these
omen without CAD suggested that low CFR could not be
xplained by left ventricular hypertrophy. We used only
lood flow velocity measurements, but we have previously
hown in an analysis from WISE that this measure agrees
losely with volumetric flow reserve (35). Finally, despite the
elatively large sample of women in this cohort, the low
umber of major events limits statistical power and creates
he risk of over-fitting the models when adding covariates.
owever, despite this potential problem, the addition of
uch covariates in no case affected the relationship between
FR and adverse outcomes.
onclusions
n women undergoing coronary angiography to further
valuate suspected ischemia, a limited coronary microvascu-
ar response to adenosine is associated with increased risk
or major adverse outcomes even in the absence of signifi-
ant obstructive CAD. This finding supports the need for
ore investigation of altered coronary smooth muscle reac-
ivity and the smaller vessels in women with suspected
schemia. Long-term follow-up of new cohorts of women
hould help to determine whether coronary microvascular
ysfunction and its link with adverse outcomes can be
onfirmed and modified.
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